EMAIL THIS PAGE TO A FRIEND

Molecular cancer research : MCR

Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells.


PMID 25733697

Abstract

While reviewing chronic lymphocytic leukemia (CLL) bone marrow slides, we identified cytoplasmic lipid vacuoles in CLL cells but not in normal B cells. Because lipoprotein lipase (LPL), which catalyzes hydrolysis of triglycerides into free fatty acids (FFA), is aberrantly expressed in CLL, we investigated whether LPL regulates the oxidative metabolic capacity of CLL cells. We found that unlike normal B cells, CLL cells metabolize FFAs. Because STAT3 is constitutively activated in CLL cells and because we identified putative STAT3 binding sites in the LPL promoter, we sought to determine whether STAT3 drives the aberrant expression of LPL. Transfection of luciferase reporter gene constructs driven by LPL promoter fragments into MM1 cells revealed that STAT3 activates the LPL promoter. In addition, chromatin immunoprecipitation confirmed that STAT3 binds to the LPL promoter. Furthermore, transfection of CLL cells with STAT3-shRNA downregulated LPL transcripts and protein levels, confirming that STAT3 activates the LPL gene. Finally, transfection of CLL cells with LPL-siRNAs decreased the capacity of CLL cells to oxidize FFAs and reduced cell viability. Our study suggests that CLL cells adopt their metabolism to oxidize FFA. Activated STAT3 induces LPL, which catalyzes the hydrolysis of triglycerides into FFA. Therefore, inhibition of STAT3 is likely to prevent the capacity of CLL cells to utilize FFA.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB2101327
Anti-LCP1 (ab1) antibody produced in rabbit, affinity isolated antibody
SAB2101328
Anti-LCP1 (ab2) antibody produced in rabbit, affinity isolated antibody
SAB2701641
Anti-lcp1 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB2701743
Anti-lcp1 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
HPA019493
Anti-LCP1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB1406091
Anti-LPL antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
SAB1401231
Anti-LPL antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
SAB2700761
Anti-LPL antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB2701143
Anti-LPL antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB2701144
Anti-LPL antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
EHU012071 MISSION® esiRNA, esiRNA targeting human LPL (esiRNA1)
EMU011931 MISSION® esiRNA, esiRNA targeting mouse Lcp1 (esiRNA1)
EHU057691 MISSION® esiRNA, esiRNA human LCP1 (esiRNA1)
EMU083541 MISSION® esiRNA, esiRNA targeting mouse Lpl (esiRNA1)
SAB5300056
Monoclonal Anti-LPL antibody produced in mouse, clone 2C5, ascites fluid